Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized poractant alfa vs nCPAP in preterm neonates with mild to moderate respiratory distress syndrome
2016-004547-36Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Safety parameters (adverse events and adverse drug reactions) and Respiratory failure. Started Feb 2017; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2016-004547-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004547-36.